Biopharmaceutical company Aptorum Group on Wednesday announced the publication of a co-authored paper on its PathsDx Test metagenomics sequencing workflow for infectious disease diagnosis.
The paper, entitled “Towards a rapid-turnaround low-depth unbiased metagenomics sequencing workflow on the Illumina platforms,” is available as a preprint on medRxiv.
PathsDx Test is a liquid biopsy-driven rapid pathogen molecular diagnostics technology designed to use next-generation sequencing platforms and proprietary artificial intelligence-based software analytics to rapidly detect and identify foreign pathogens (virus, bacteria, fungus, parasites) without bias through their genome composition.
“These results are remarkable as an initial stage of clinical validation,” Dr. Clark Cheng, chief medical officer of Aptorum Group, said in a statement. “We are also pleased to now have built up a pathogen genomic database of close to 20,000 species to support our software analytics in identifying, on an unbiased metagenomic basis, the pathogenic composition in the patient sample."
Given the results of the study, the firm is expanding its validation sites in Singapore, Hong Kong, and U.S.
